Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Total Liabilities (2021 - 2025)

Historic Total Liabilities for Indivior Pharmaceuticals (INDV) over the last 5 years, with Q3 2025 value amounting to $1.6 billion.

  • Indivior Pharmaceuticals' Total Liabilities rose 19950.95% to $1.6 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 billion, marking a year-over-year increase of 19950.95%. This contributed to the annual value of $1.7 billion for FY2024, which is 1493.31% down from last year.
  • Latest data reveals that Indivior Pharmaceuticals reported Total Liabilities of $1.6 billion as of Q3 2025, which was up 19950.95% from $1.7 billion recorded in Q2 2025.
  • In the past 5 years, Indivior Pharmaceuticals' Total Liabilities registered a high of $1.9 billion during Q4 2023, and its lowest value of -$1.9 billion during Q3 2023.
  • Moreover, its 5-year median value for Total Liabilities was $1.6 billion (2021), whereas its average is $309.4 million.
  • In the last 5 years, Indivior Pharmaceuticals' Total Liabilities tumbled by 1493.31% in 2024 and then skyrocketed by 21503.81% in 2025.
  • Over the past 5 years, Indivior Pharmaceuticals' Total Liabilities (Quarter) stood at $1.6 billion in 2021, then rose by 5.46% to $1.7 billion in 2022, then rose by 13.04% to $1.9 billion in 2023, then fell by 14.93% to $1.7 billion in 2024, then decreased by 1.76% to $1.6 billion in 2025.
  • Its Total Liabilities was $1.6 billion in Q3 2025, compared to $1.7 billion in Q2 2025 and $1.7 billion in Q1 2025.